|
Mutation Information
|
Mutation Site
|
M204V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204V+rt.L180M;rt.N236T+rt.M204V+rt.L180M |
|
Genotype/Subtype
|
D |
|
Relevant Drug
|
adefovir (ADV);lamivudine (LAM);emtricitabine (FTC);clevudine (L-FMAU);Elvucitabine (β‐L‐FD4C) |
Literature Information
|
PubMed PMID
|
15915463
|
|
Published Year
|
2005 |
|
Journal
|
Hepatology (Baltimore, Md.) |
|
Title
|
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. |
|
Author
|
Brunelle MN,Jacquard AC,Pichoud C,Durantel D,Carrouée-Durantel S,Villeneuve JP,Trépo C,Zoulim F |
|
Evidence
|
Phenotypic assays indicated that the L180M+M204V+N236T mutant is resistant to pyrimidine analogs (3TC, -FTC, beta-L-FD4C, L-FMAU).
|
|
|
HBV Mutation Detail Information